{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for folic root_modifications_structuralModifications_structuralModificationType in Structural Modification Type (approximate match)
Status:
US Approved Rx
(2023)
Source:
BLA761161
(2023)
Source URL:
First approved in 2023
Source:
BLA761161
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2023)
Source:
BLA761309
(2023)
Source URL:
First approved in 2023
Source:
BLA761309
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
NDA215866
(2022)
Source URL:
First approved in 2022
Source:
NDA215866
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761148
(2022)
Source URL:
First approved in 2022
Source:
BLA761148
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
NDA022231
(2022)
Source URL:
First approved in 2022
Source:
NDA022231
Source URL:
Class:
PROTEIN
Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors.
Status:
US Approved Rx
(2021)
Source:
NDA214231
(2021)
Source URL:
First approved in 2021
Source:
NDA214231
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761171
(2020)
Source URL:
First approved in 2020
Source:
BLA761171
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761113
(2020)
Source URL:
First approved in 2020
Source:
BLA761113
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761156
(2020)
Source URL:
First approved in 2020
Source:
BLA761156
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761142
(2020)
Source URL:
First approved in 2020
Source:
BLA761142
Source URL:
Class:
PROTEIN
